1h Free Analyst Time
Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Gamma-aminobutyric acid receptor subunit gamma-2 is a protein encoded by the GABRG2 gene. It functions also as histamine receptor and mediates cellular responses to histamine. It functions as receptor for diazepines and various anesthetics and as ligand-gated chloride channel.
The molecules developed by companies in Pre-Registration, Phase III and Preclinical stages are 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. The report covers products from therapy areas Central Nervous System and Metabolic Disorders which include indications Sedation, General Anesthetic Effect, Hypercholesterolemia, Status Epilepticus and Substance (Drug) Abuse.
Furthermore, this report also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)
- The report reviews Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Overview
- Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Companies Involved in Therapeutics Development
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Nhwa Pharmaceutical Co Ltd
- Paion AG
- Takeda Pharmaceutical Co Ltd
- Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Drug Profiles
- clonazepam - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- EL-001 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- HR-7056 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- LASSBio-785 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- midazolam hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- remimazolam besylate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Dormant Products
- Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Discontinued Products
- Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Product Development Milestones
- Featured News & Press Releases
- Mar 12, 2020: Acacia Pharma announces brief extension of FDA review period for NDA for BYFAVO
- Jan 23, 2020: PAION : Mundipharma receives market approval for Anerem (Remimazolam) in general anesthesia in Japan
- Dec 30, 2019: Paion announces submission of new drug application for remimazolam by its licensee Hana Pharm in South Korea
- Nov 20, 2019: Paion announces submission of the marketing authorization application for Remimazolam in procedural sedation to the European Medicines Agency
- Jun 28, 2019: EIB and German specialty pharmaceutical company PAION AG have signed a €20 million loan agreement
- Jun 11, 2019: Hana Pharm presented clinical trial results of Remimazolam at International Congress of Cardiothoracic and Vascular Anesthesia
- Jun 10, 2019: FDA accepts filing of NDA for Remimazolam
- Apr 09, 2019: Cosmo Pharmaceuticals announces submission of Remimazolam NDA to FDA
- Nov 06, 2018: R-Pharm Group and Paion announce successful completion of remimazolam phase III clinical trial
- Oct 08, 2018: PAION announces clinical development progress with Remimazolam by its partner Hana Pharm in South Korea
- Jul 24, 2018: PAION starts EU Phase III trial with remimazolam in general anesthesia
- May 17, 2018: Paion announces clinical development progress with Remimazolam by its partner R-Pharm in Russia
- Jan 15, 2018: European Medicines Agency: Defect with Buccolam oral syringes
- Nov 23, 2017: PAION Announces Clinical Development Progress with Remimazolam by its Partner Hana Pharma in South Koera
- Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with Remimazolam in the U.S. As Sufficient; no Second Intranasal Study Required
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Information
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Indication, H1 2020
- Number of Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020
- Number of Products under Investigation by Universities/Institutes, H1 2020
- Products under Investigation by Universities/Institutes, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
- Pipeline by Jiangsu Nhwa Pharmaceutical Co Ltd, H1 2020
- Pipeline by Paion AG, H1 2020
- Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
- Dormant Projects, H1 2020
- Discontinued Products, H1 2020
List of Figures
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Top 10 Indications, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Routes of Administration, H1 2020
- Number of Products by Stage and Routes of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Nhwa Pharmaceutical Co Ltd
- Paion AG
- Takeda Pharmaceutical Co Ltd
